Drugs and Vaccines Will Be Necessary to Control Tuberculosis
Source abstract
Abstract
For most infectious diseases, vaccines are used to prevent infection and drugs are used for acute therapy and eradication of established infections [...]
Only a short abstract or summary was supplied by the source.
Source: crossref · Quality: short
Research context
OpenAlex topics: Immune responses and vaccinations · Tuberculosis Research and Epidemiology · SARS-CoV-2 and COVID-19 Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
GSK, 53100 Siena, Italy
Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy
Imperial College London, London SW7 2AZ, UK
References (6)
Show source-provided references
1. Martin, C., Aguilo, N., Marinova, D., and Gonzalo-Asensio, J. (2020). Update on TB vaccine pipeline. Appl. Sci., 10.10.3390/app10072632 ↗
2. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin10.1172/JCI24617 ↗
3. Loxton, A.G., Knaul, J.K., Grode, L., Gutschmidt, A., Meller, C., Eisele, B., Johnstone, H., van der Spuy, G., Maertzdorf, J., and Kaufmann, S.H.E. (2017). Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin. Vaccine Immunol. CVI, 24.10.1128/CVI.00439-16 ↗
4. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination10.1056/NEJMoa1714021 ↗
5. Final Analysis of a Trial of M72/AS01(E) Vaccine to Prevent Tuberculosis10.1056/NEJMoa1909953 ↗
6. Phase 2b Controlled Trial of M72/AS01(E) Vaccine to Prevent Tuberculosis10.1056/NEJMoa1803484 ↗